Antitumor antibiotic complex and third generation analog of bleomycins, q.v., produced by Streptoalloteichus hindustanus E 465-94. Prodn, isoln, properties of the major components, tallysomycins A and B: H. Kawaguchi et al., BE 845513; eidem, US 4051237 (both 1977 to Bristol-Myers); eidem, J. Antibiot. 30, 779 (1977). Structure of A and B, based on originally proposed bleomycin structure: M. Konishi et al., ibid. 789; cf. bleomycin for revised structure. Antitumor activity: H. Imanishi et al., ibid. 31, 667 (1978). Radioimmunoassay: A. Broughton et al., Cancer Treat. Rep. 63, 1829 (1979). Pharmacokinetics: J. E. Strong et al., ibid. 1821. 13C-NMR spectra of tallysomycin and its zinc complex: F. T. Greenaway et al., Org. Magn. Reson. 13, 270 (1980). Biosynthetic derivs: T. Miyaki et al., J. Antibiot. 34, 658, 665 (1981). Relative pulmonary toxicity: A. Broughton et al., Cancer Treat. Rep. 64, 659 (1980). Review: S. T. Crooke et al., Recent Results Cancer Res. 76, 83-90 (1981).
The term “talisomycin” has also been used to refer to tallysomycin A.